Barbara M Norquist

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. pmc The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations
    Barbara M Norquist
    Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA, USA
    Cancer 116:5261-71. 2010
  2. doi request reprint Characteristics of women with ovarian carcinoma who have BRCA1 and BRCA2 mutations not identified by clinical testing
    Barbara M Norquist
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Box 356460, University of Washington School of Medicine, Seattle, WA 98195, USA
    Gynecol Oncol 128:483-7. 2013
  3. doi request reprint 53BP1 expression in sporadic and inherited ovarian carcinoma: Relationship to genetic status and clinical outcomes
    Kathryn P Pennington
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195, USA
    Gynecol Oncol 128:493-9. 2013
  4. pmc Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriers
    Joshua Z Press
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195, USA
    Neoplasia 12:993-1002. 2010
  5. pmc Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer
    Silvia Casadei
    Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, Washington 98195, USA
    Cancer Res 71:2222-9. 2011

Collaborators

Detail Information

Publications5

  1. pmc The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations
    Barbara M Norquist
    Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA, USA
    Cancer 116:5261-71. 2010
    ..BRCA1 or BRCA2 (BRCA1/2)-mutated ovarian carcinomas may originate in the fallopian tube. The authors of this report investigated alterations in BRCA1/2 tubal epithelium to define the molecular pathogenesis of these carcinomas...
  2. doi request reprint Characteristics of women with ovarian carcinoma who have BRCA1 and BRCA2 mutations not identified by clinical testing
    Barbara M Norquist
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Box 356460, University of Washington School of Medicine, Seattle, WA 98195, USA
    Gynecol Oncol 128:483-7. 2013
    ..We sought to determine if clinically identified mutation carriers differed in clinical characteristics and outcomes from mutation carriers not identified during routine clinical care...
  3. doi request reprint 53BP1 expression in sporadic and inherited ovarian carcinoma: Relationship to genetic status and clinical outcomes
    Kathryn P Pennington
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195, USA
    Gynecol Oncol 128:493-9. 2013
    ..We characterized 53BP1 and BRCA1 expression and their association with clinical outcomes in sporadic and inherited ovarian carcinomas...
  4. pmc Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriers
    Joshua Z Press
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195, USA
    Neoplasia 12:993-1002. 2010
    ..The expression of a subset of genes was validated with quantitative reverse transcription-polymerase chain reaction and immunohistochemistry...
  5. pmc Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer
    Silvia Casadei
    Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, Washington 98195, USA
    Cancer Res 71:2222-9. 2011
    ..Given this mutation prevalence and risk, consideration might be given to clinical testing of PALB2 by complete genomic sequencing for familial breast cancer patients with wild-type sequences at BRCA1 and BRCA2...